AN2 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights

MENLO PARK, Calif.–(BUSINESS WIRE)–AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended December 31, 2022. “2022 was a transformative year for AN2 as we…